 Rohit Katial
Concepts (420)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 52 | 2024 | 2265 | 5.520 |
Why?
| | Anti-Asthmatic Agents | 22 | 2024 | 377 | 4.310 |
Why?
| | Hypersensitivity | 9 | 2024 | 280 | 2.830 |
Why?
| | Aspirin | 11 | 2018 | 383 | 2.690 |
Why?
| | Respiratory Tract Diseases | 6 | 2016 | 151 | 2.300 |
Why?
| | Rhinitis, Allergic, Perennial | 8 | 2018 | 24 | 2.240 |
Why?
| | Rhinitis, Allergic, Seasonal | 8 | 2012 | 33 | 2.200 |
Why?
| | Sinusitis | 11 | 2024 | 205 | 2.190 |
Why?
| | Biological Products | 9 | 2024 | 203 | 2.180 |
Why?
| | Rhinitis | 7 | 2024 | 152 | 1.640 |
Why?
| | Adrenal Cortex Hormones | 14 | 2024 | 527 | 1.540 |
Why?
| | Eosinophils | 16 | 2024 | 326 | 1.490 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 7 | 2018 | 345 | 1.410 |
Why?
| | Nitric Oxide | 8 | 2024 | 896 | 1.400 |
Why?
| | Antibodies, Monoclonal, Humanized | 15 | 2024 | 763 | 1.370 |
Why?
| | Nasal Polyps | 7 | 2024 | 58 | 1.360 |
Why?
| | Rhinitis, Allergic | 4 | 2024 | 44 | 1.300 |
Why?
| | Eosinophilic Esophagitis | 2 | 2024 | 333 | 1.300 |
Why?
| | Eosinophilia | 7 | 2024 | 207 | 1.190 |
Why?
| | Allergens | 7 | 2024 | 465 | 1.170 |
Why?
| | Immunoglobulin E | 6 | 2024 | 356 | 1.160 |
Why?
| | Histamine Antagonists | 4 | 2011 | 21 | 1.150 |
Why?
| | Skin Tests | 3 | 2024 | 126 | 1.140 |
Why?
| | Mast Cells | 3 | 2023 | 145 | 1.100 |
Why?
| | Cost of Illness | 3 | 2024 | 292 | 1.060 |
Why?
| | Exhalation | 2 | 2018 | 38 | 1.000 |
Why?
| | Anti-Allergic Agents | 4 | 2018 | 50 | 0.980 |
Why?
| | Desensitization, Immunologic | 4 | 2016 | 136 | 0.940 |
Why?
| | Immunologic Deficiency Syndromes | 3 | 2016 | 64 | 0.910 |
Why?
| | Immunotherapy | 5 | 2017 | 599 | 0.900 |
Why?
| | Angioedema | 1 | 2024 | 17 | 0.890 |
Why?
| | Humans | 108 | 2025 | 130305 | 0.870 |
Why?
| | Mastocytosis | 1 | 2023 | 13 | 0.870 |
Why?
| | Urticaria | 1 | 2024 | 42 | 0.860 |
Why?
| | Proton Pump Inhibitors | 1 | 2024 | 104 | 0.850 |
Why?
| | Severity of Illness Index | 13 | 2024 | 2785 | 0.850 |
Why?
| | Gastritis | 1 | 2024 | 98 | 0.810 |
Why?
| | Deglutition Disorders | 1 | 2024 | 130 | 0.810 |
Why?
| | Enteritis | 1 | 2024 | 95 | 0.810 |
Why?
| | Biomarkers | 8 | 2024 | 3923 | 0.740 |
Why?
| | Pancreatitis | 2 | 2012 | 129 | 0.730 |
Why?
| | Albuterol | 3 | 2010 | 105 | 0.720 |
Why?
| | Allergy and Immunology | 2 | 2024 | 60 | 0.710 |
Why?
| | Patient Reported Outcome Measures | 1 | 2024 | 363 | 0.710 |
Why?
| | Breath Tests | 4 | 2007 | 91 | 0.680 |
Why?
| | Androstadienes | 2 | 2010 | 107 | 0.670 |
Why?
| | Sputum | 4 | 2024 | 309 | 0.650 |
Why?
| | Drug Hypersensitivity | 4 | 2016 | 92 | 0.620 |
Why?
| | Bronchial Provocation Tests | 3 | 2018 | 50 | 0.590 |
Why?
| | Biological Therapy | 1 | 2017 | 30 | 0.540 |
Why?
| | STAT6 Transcription Factor | 1 | 2016 | 26 | 0.520 |
Why?
| | Adult | 42 | 2025 | 35711 | 0.510 |
Why?
| | Insect Bites and Stings | 1 | 2016 | 14 | 0.510 |
Why?
| | Antibodies, Monoclonal | 3 | 2018 | 1372 | 0.480 |
Why?
| | Administration, Intranasal | 6 | 2011 | 84 | 0.470 |
Why?
| | Vaccination | 3 | 2012 | 1361 | 0.470 |
Why?
| | Practice Guidelines as Topic | 7 | 2024 | 1537 | 0.470 |
Why?
| | Middle Aged | 32 | 2025 | 31322 | 0.450 |
Why?
| | Remission Induction | 2 | 2024 | 270 | 0.440 |
Why?
| | Forced Expiratory Volume | 3 | 2018 | 509 | 0.420 |
Why?
| | Anaphylaxis | 1 | 2016 | 161 | 0.420 |
Why?
| | Double-Blind Method | 9 | 2024 | 1878 | 0.410 |
Why?
| | Male | 40 | 2025 | 63748 | 0.390 |
Why?
| | Female | 42 | 2025 | 68842 | 0.380 |
Why?
| | Bronchial Hyperreactivity | 3 | 2018 | 105 | 0.380 |
Why?
| | Treatment Outcome | 18 | 2024 | 10341 | 0.380 |
Why?
| | T-Lymphocyte Subsets | 2 | 2009 | 412 | 0.380 |
Why?
| | Chronic Disease | 9 | 2024 | 1727 | 0.370 |
Why?
| | Disease Progression | 5 | 2023 | 2639 | 0.360 |
Why?
| | Young Adult | 13 | 2025 | 12404 | 0.350 |
Why?
| | Pulmonary Eosinophilia | 2 | 2022 | 28 | 0.340 |
Why?
| | Dermatitis, Atopic | 2 | 2024 | 335 | 0.330 |
Why?
| | Aged | 13 | 2024 | 22282 | 0.330 |
Why?
| | Acetates | 1 | 2010 | 99 | 0.320 |
Why?
| | Vaccines | 2 | 2004 | 404 | 0.310 |
Why?
| | Nose | 1 | 2009 | 66 | 0.310 |
Why?
| | Quinolines | 1 | 2010 | 149 | 0.310 |
Why?
| | United States | 7 | 2024 | 14110 | 0.300 |
Why?
| | Laryngismus | 1 | 2008 | 6 | 0.300 |
Why?
| | Leukotriene E4 | 1 | 2008 | 26 | 0.300 |
Why?
| | Vocal Cords | 1 | 2008 | 32 | 0.290 |
Why?
| | Immunity, Cellular | 2 | 2007 | 269 | 0.290 |
Why?
| | Adolescent | 13 | 2024 | 20374 | 0.290 |
Why?
| | Diagnosis, Differential | 5 | 2017 | 1442 | 0.280 |
Why?
| | Gastrointestinal Diseases | 1 | 2009 | 201 | 0.270 |
Why?
| | Paranasal Sinuses | 2 | 2020 | 74 | 0.270 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2009 | 381 | 0.250 |
Why?
| | Ethyl Chloride | 1 | 2005 | 1 | 0.250 |
Why?
| | Matrix Metalloproteinase 9 | 3 | 2011 | 121 | 0.250 |
Why?
| | Quality of Life | 5 | 2024 | 2735 | 0.250 |
Why?
| | Respiratory Tract Infections | 2 | 2004 | 373 | 0.250 |
Why?
| | Mastocytosis, Systemic | 1 | 2005 | 8 | 0.240 |
Why?
| | Alternaria | 2 | 2002 | 9 | 0.240 |
Why?
| | Conjunctivitis, Allergic | 1 | 2004 | 4 | 0.240 |
Why?
| | Nebulizers and Vaporizers | 3 | 2015 | 82 | 0.240 |
Why?
| | Immunoglobulin G | 2 | 2025 | 845 | 0.240 |
Why?
| | Anesthetics, Local | 1 | 2005 | 85 | 0.230 |
Why?
| | Heartburn | 1 | 2024 | 12 | 0.230 |
Why?
| | Analgesia | 1 | 2005 | 94 | 0.230 |
Why?
| | Food Hypersensitivity | 2 | 2009 | 286 | 0.230 |
Why?
| | Cytokines | 3 | 2016 | 2016 | 0.230 |
Why?
| | Gastroesophageal Reflux | 2 | 2024 | 240 | 0.230 |
Why?
| | Syphilis | 1 | 2004 | 31 | 0.230 |
Why?
| | Antigens, Bacterial | 2 | 2002 | 120 | 0.230 |
Why?
| | Serum Sickness | 1 | 2004 | 7 | 0.230 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2004 | 74 | 0.220 |
Why?
| | Bupropion | 1 | 2004 | 41 | 0.220 |
Why?
| | Bioterrorism | 1 | 2004 | 24 | 0.220 |
Why?
| | Exanthema | 1 | 2004 | 76 | 0.220 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2004 | 55 | 0.220 |
Why?
| | Administration, Inhalation | 3 | 2016 | 675 | 0.220 |
Why?
| | Cockroaches | 1 | 2003 | 21 | 0.220 |
Why?
| | Geography | 1 | 2024 | 188 | 0.210 |
Why?
| | Research Design | 1 | 2009 | 1052 | 0.210 |
Why?
| | Child | 9 | 2024 | 20961 | 0.210 |
Why?
| | Signal Transduction | 2 | 2016 | 4930 | 0.210 |
Why?
| | Recurrence | 2 | 2017 | 1020 | 0.210 |
Why?
| | Glycoproteins | 2 | 2002 | 340 | 0.210 |
Why?
| | Lolium | 1 | 2002 | 2 | 0.200 |
Why?
| | Age of Onset | 1 | 2024 | 499 | 0.200 |
Why?
| | Interferon-gamma | 3 | 2016 | 766 | 0.190 |
Why?
| | Pulmonary Atelectasis | 1 | 2002 | 14 | 0.190 |
Why?
| | Neisseria meningitidis | 1 | 2002 | 22 | 0.190 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2022 | 92 | 0.190 |
Why?
| | Poaceae | 1 | 2002 | 81 | 0.190 |
Why?
| | Clinical Trials as Topic | 4 | 2011 | 1015 | 0.190 |
Why?
| | Polysaccharides, Bacterial | 1 | 2002 | 67 | 0.190 |
Why?
| | Meningococcal Vaccines | 1 | 2002 | 53 | 0.190 |
Why?
| | Bacterial Outer Membrane Proteins | 1 | 2002 | 58 | 0.190 |
Why?
| | Vaccines, Synthetic | 1 | 2002 | 129 | 0.190 |
Why?
| | Adrenal Insufficiency | 1 | 2021 | 32 | 0.180 |
Why?
| | Tuberculin | 1 | 2001 | 8 | 0.180 |
Why?
| | Hypersensitivity, Delayed | 1 | 2001 | 28 | 0.180 |
Why?
| | Tuberculin Test | 1 | 2001 | 34 | 0.180 |
Why?
| | Fluticasone-Salmeterol Drug Combination | 2 | 2010 | 12 | 0.180 |
Why?
| | Reference Values | 4 | 2007 | 793 | 0.170 |
Why?
| | Bronchodilator Agents | 1 | 2022 | 252 | 0.170 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2001 | 137 | 0.170 |
Why?
| | Algorithms | 4 | 2020 | 1638 | 0.160 |
Why?
| | Receptors, Leukotriene | 2 | 2016 | 13 | 0.160 |
Why?
| | Lung | 2 | 2007 | 3967 | 0.160 |
Why?
| | Drug Combinations | 2 | 2010 | 328 | 0.160 |
Why?
| | Chickenpox Vaccine | 1 | 1999 | 71 | 0.160 |
Why?
| | Histamine | 2 | 2011 | 65 | 0.150 |
Why?
| | Tosyl Compounds | 1 | 1998 | 15 | 0.150 |
Why?
| | STAT1 Transcription Factor | 2 | 2016 | 70 | 0.150 |
Why?
| | Theophylline | 1 | 1998 | 66 | 0.150 |
Why?
| | Bacterial Capsules | 2 | 2012 | 28 | 0.150 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2018 | 29 | 0.150 |
Why?
| | Lamiaceae | 1 | 1997 | 2 | 0.150 |
Why?
| | Artemisia | 1 | 1997 | 7 | 0.140 |
Why?
| | Plants, Medicinal | 1 | 1997 | 22 | 0.140 |
Why?
| | Meteorological Concepts | 1 | 1997 | 6 | 0.140 |
Why?
| | Mycobacterium tuberculosis | 1 | 2001 | 316 | 0.140 |
Why?
| | Primary Health Care | 1 | 2008 | 1677 | 0.140 |
Why?
| | Benzamides | 1 | 2018 | 195 | 0.140 |
Why?
| | Aging | 1 | 2007 | 1785 | 0.140 |
Why?
| | Spores, Fungal | 1 | 1997 | 22 | 0.140 |
Why?
| | Drug Therapy, Combination | 3 | 2023 | 1028 | 0.140 |
Why?
| | Lymphocytosis | 1 | 1997 | 10 | 0.140 |
Why?
| | Air Microbiology | 1 | 1997 | 41 | 0.140 |
Why?
| | Pyrroles | 1 | 2018 | 204 | 0.140 |
Why?
| | Common Variable Immunodeficiency | 1 | 1997 | 27 | 0.130 |
Why?
| | Leukotrienes | 1 | 2016 | 34 | 0.130 |
Why?
| | Molecular Targeted Therapy | 2 | 2017 | 389 | 0.130 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 1997 | 99 | 0.130 |
Why?
| | Interleukin-4 | 3 | 2013 | 214 | 0.130 |
Why?
| | Allergists | 1 | 2016 | 19 | 0.130 |
Why?
| | Bacterial Toxins | 1 | 1997 | 107 | 0.130 |
Why?
| | Comorbidity | 4 | 2024 | 1555 | 0.130 |
Why?
| | Registries | 4 | 2024 | 1934 | 0.130 |
Why?
| | Venoms | 1 | 2016 | 30 | 0.130 |
Why?
| | Interleukins | 2 | 2013 | 247 | 0.130 |
Why?
| | Canada | 1 | 2017 | 356 | 0.120 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 1 | 2016 | 37 | 0.120 |
Why?
| | Insecta | 1 | 2016 | 66 | 0.120 |
Why?
| | Anti-Inflammatory Agents | 2 | 2012 | 475 | 0.120 |
Why?
| | Herpesvirus 3, Human | 1 | 1999 | 400 | 0.120 |
Why?
| | Drugs, Generic | 1 | 2015 | 19 | 0.120 |
Why?
| | Cardiac Tamponade | 1 | 1994 | 15 | 0.120 |
Why?
| | Papilloma | 1 | 1994 | 46 | 0.120 |
Why?
| | Leukocytes, Mononuclear | 1 | 1998 | 550 | 0.120 |
Why?
| | Bronchial Diseases | 1 | 1994 | 39 | 0.120 |
Why?
| | Tumor Virus Infections | 1 | 1994 | 48 | 0.120 |
Why?
| | Pentamidine | 1 | 1994 | 4 | 0.120 |
Why?
| | Gallium Radioisotopes | 1 | 1994 | 14 | 0.120 |
Why?
| | Epinephrine | 1 | 2016 | 180 | 0.110 |
Why?
| | Pneumonia, Pneumocystis | 1 | 1994 | 34 | 0.110 |
Why?
| | Phosphorylation | 2 | 2016 | 1709 | 0.110 |
Why?
| | Papillomaviridae | 1 | 1994 | 113 | 0.110 |
Why?
| | Animals | 7 | 2017 | 35076 | 0.110 |
Why?
| | Cohort Studies | 4 | 2024 | 5431 | 0.110 |
Why?
| | Basophils | 2 | 2013 | 72 | 0.110 |
Why?
| | Aerosols | 3 | 2001 | 173 | 0.110 |
Why?
| | Bronchiectasis | 1 | 1994 | 112 | 0.110 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2002 | 827 | 0.110 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 1994 | 124 | 0.110 |
Why?
| | Guidelines as Topic | 1 | 2015 | 262 | 0.100 |
Why?
| | Pharmaceutical Preparations | 1 | 2015 | 172 | 0.100 |
Why?
| | Rabies Vaccines | 1 | 2012 | 2 | 0.100 |
Why?
| | Drug Resistance | 1 | 2013 | 168 | 0.100 |
Why?
| | Olfaction Disorders | 1 | 2013 | 60 | 0.100 |
Why?
| | Salmonella Vaccines | 1 | 2012 | 2 | 0.100 |
Why?
| | Bacteriophage phi X 174 | 1 | 2012 | 5 | 0.100 |
Why?
| | T-Lymphocytes | 2 | 2016 | 1928 | 0.100 |
Why?
| | Haemophilus Vaccines | 1 | 2012 | 28 | 0.100 |
Why?
| | Evidence-Based Medicine | 1 | 2017 | 733 | 0.100 |
Why?
| | Receptors, Histamine | 1 | 2011 | 5 | 0.100 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2011 | 25 | 0.090 |
Why?
| | Retrospective Studies | 6 | 2024 | 14675 | 0.090 |
Why?
| | History, 19th Century | 1 | 2011 | 57 | 0.090 |
Why?
| | Immunity, Humoral | 1 | 2012 | 121 | 0.090 |
Why?
| | Pneumococcal Vaccines | 1 | 2012 | 141 | 0.090 |
Why?
| | Papillomavirus Infections | 1 | 1994 | 291 | 0.090 |
Why?
| | Salmeterol Xinafoate | 1 | 2010 | 41 | 0.090 |
Why?
| | Fluticasone | 1 | 2010 | 90 | 0.090 |
Why?
| | Health Surveys | 2 | 2012 | 495 | 0.090 |
Why?
| | Respiratory Mucosa | 1 | 2013 | 314 | 0.090 |
Why?
| | History, 20th Century | 1 | 2011 | 297 | 0.080 |
Why?
| | Phenotype | 2 | 2017 | 3084 | 0.080 |
Why?
| | Cyclopropanes | 1 | 2010 | 88 | 0.080 |
Why?
| | Receptors, IgG | 1 | 2009 | 73 | 0.080 |
Why?
| | Congresses as Topic | 1 | 2011 | 218 | 0.080 |
Why?
| | Chemokine CCL26 | 1 | 2009 | 9 | 0.080 |
Why?
| | Sulfides | 1 | 2010 | 94 | 0.080 |
Why?
| | Medication Adherence | 1 | 2014 | 577 | 0.080 |
Why?
| | Clinical Competence | 1 | 2016 | 1029 | 0.080 |
Why?
| | Bone Marrow | 2 | 2013 | 267 | 0.080 |
Why?
| | Chemokines, CC | 1 | 2009 | 33 | 0.080 |
Why?
| | Administration, Oral | 1 | 2011 | 788 | 0.080 |
Why?
| | Leukocyte Count | 2 | 2024 | 328 | 0.080 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2009 | 77 | 0.080 |
Why?
| | United States Food and Drug Administration | 1 | 2009 | 205 | 0.080 |
Why?
| | Case-Control Studies | 1 | 2016 | 3369 | 0.070 |
Why?
| | Antibodies, Viral | 2 | 2025 | 607 | 0.070 |
Why?
| | Interleukin-13 | 1 | 2009 | 148 | 0.070 |
Why?
| | Adenosine | 1 | 2009 | 213 | 0.070 |
Why?
| | Kartagener Syndrome | 1 | 2007 | 30 | 0.070 |
Why?
| | Vasodilator Agents | 1 | 2009 | 325 | 0.070 |
Why?
| | Recombinant Fusion Proteins | 1 | 2010 | 645 | 0.070 |
Why?
| | Bronchiolitis Obliterans | 1 | 2007 | 71 | 0.070 |
Why?
| | Infant, Newborn | 1 | 2018 | 5741 | 0.070 |
Why?
| | Longitudinal Studies | 2 | 2024 | 2691 | 0.070 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2013 | 1056 | 0.070 |
Why?
| | Health Status | 1 | 2012 | 756 | 0.070 |
Why?
| | Transforming Growth Factor beta | 1 | 2009 | 465 | 0.060 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2009 | 533 | 0.060 |
Why?
| | Flushing | 1 | 2005 | 1 | 0.060 |
Why?
| | Administration, Topical | 1 | 2005 | 148 | 0.060 |
Why?
| | Penicillin G | 1 | 2004 | 7 | 0.060 |
Why?
| | Acute Disease | 1 | 2008 | 981 | 0.060 |
Why?
| | New Zealand | 1 | 2025 | 46 | 0.060 |
Why?
| | Histamine H1 Antagonists | 1 | 2004 | 30 | 0.060 |
Why?
| | Mutation | 1 | 2016 | 3723 | 0.060 |
Why?
| | Infant | 1 | 2018 | 9049 | 0.060 |
Why?
| | Methylprednisolone Hemisuccinate | 1 | 2004 | 2 | 0.060 |
Why?
| | Biomedical Research | 1 | 2011 | 658 | 0.060 |
Why?
| | Dependovirus | 1 | 2025 | 60 | 0.060 |
Why?
| | Arenaviruses, New World | 1 | 2004 | 3 | 0.060 |
Why?
| | Clostridium botulinum | 1 | 2004 | 4 | 0.060 |
Why?
| | China | 1 | 2025 | 192 | 0.060 |
Why?
| | Anthrax Vaccines | 1 | 2004 | 7 | 0.060 |
Why?
| | Diarrhea | 1 | 2005 | 179 | 0.060 |
Why?
| | Smallpox Vaccine | 1 | 2004 | 22 | 0.060 |
Why?
| | Placebos | 2 | 2018 | 204 | 0.060 |
Why?
| | Membrane Proteins | 1 | 2010 | 1121 | 0.060 |
Why?
| | Child, Preschool | 1 | 2018 | 10514 | 0.060 |
Why?
| | Yersinia pestis | 1 | 2004 | 44 | 0.050 |
Why?
| | Francisella tularensis | 1 | 2004 | 30 | 0.050 |
Why?
| | Headache | 1 | 2004 | 139 | 0.050 |
Why?
| | Bacterial Vaccines | 1 | 2004 | 62 | 0.050 |
Why?
| | Insect Control | 1 | 2003 | 11 | 0.050 |
Why?
| | Classification | 1 | 2003 | 18 | 0.050 |
Why?
| | Food Contamination | 1 | 2003 | 43 | 0.050 |
Why?
| | Genetic Vectors | 1 | 2025 | 314 | 0.050 |
Why?
| | Adjuvants, Immunologic | 1 | 2004 | 220 | 0.050 |
Why?
| | Multimorbidity | 1 | 2023 | 45 | 0.050 |
Why?
| | Disease Transmission, Infectious | 1 | 2003 | 57 | 0.050 |
Why?
| | Viral Vaccines | 1 | 2004 | 93 | 0.050 |
Why?
| | Pain Measurement | 1 | 2005 | 491 | 0.050 |
Why?
| | Disaster Planning | 1 | 2004 | 84 | 0.050 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2023 | 96 | 0.050 |
Why?
| | Genetic Therapy | 1 | 2025 | 296 | 0.050 |
Why?
| | Antigens, Dermatophagoides | 1 | 2002 | 10 | 0.050 |
Why?
| | Cluster Analysis | 1 | 2024 | 485 | 0.050 |
Why?
| | Referral and Consultation | 1 | 2008 | 736 | 0.050 |
Why?
| | Insurance Claim Review | 1 | 2022 | 75 | 0.050 |
Why?
| | Immunoglobulin Isotypes | 1 | 2002 | 36 | 0.050 |
Why?
| | Consumer Product Safety | 1 | 2002 | 30 | 0.050 |
Why?
| | Aspergillosis, Allergic Bronchopulmonary | 1 | 2002 | 11 | 0.050 |
Why?
| | Menstruation | 1 | 2002 | 44 | 0.050 |
Why?
| | Drug Tolerance | 1 | 2002 | 82 | 0.050 |
Why?
| | Time Factors | 2 | 2010 | 6615 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 1994 | 2376 | 0.050 |
Why?
| | Aged, 80 and over | 1 | 2013 | 7128 | 0.050 |
Why?
| | Recombinant Proteins | 1 | 2025 | 1314 | 0.050 |
Why?
| | Mycobacterium avium | 1 | 2001 | 22 | 0.050 |
Why?
| | Antibodies, Bacterial | 1 | 2002 | 138 | 0.050 |
Why?
| | Plant Extracts | 1 | 2002 | 180 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2024 | 1510 | 0.040 |
Why?
| | Health Care Costs | 1 | 2023 | 407 | 0.040 |
Why?
| | Ultrasonic Therapy | 1 | 2000 | 12 | 0.040 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2004 | 400 | 0.040 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2007 | 986 | 0.040 |
Why?
| | Respiratory Mechanics | 1 | 2000 | 65 | 0.040 |
Why?
| | Neutrophils | 2 | 2017 | 1209 | 0.040 |
Why?
| | Inflammation | 1 | 2010 | 2721 | 0.040 |
Why?
| | In Vitro Techniques | 1 | 2001 | 1067 | 0.040 |
Why?
| | Pregnancy | 1 | 2011 | 6301 | 0.040 |
Why?
| | Phenylcarbamates | 1 | 1998 | 4 | 0.040 |
Why?
| | Uricosuric Agents | 1 | 1998 | 2 | 0.040 |
Why?
| | Public Health | 1 | 2003 | 496 | 0.040 |
Why?
| | Probenecid | 1 | 1998 | 8 | 0.040 |
Why?
| | Bronchoconstrictor Agents | 1 | 2018 | 16 | 0.040 |
Why?
| | S-Nitrosoglutathione | 1 | 2018 | 7 | 0.040 |
Why?
| | Leukotriene Antagonists | 1 | 1998 | 43 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 1 | 1999 | 393 | 0.040 |
Why?
| | Methacholine Chloride | 1 | 2018 | 51 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 2 | 2020 | 2551 | 0.040 |
Why?
| | Pokeweed Mitogens | 1 | 1998 | 7 | 0.040 |
Why?
| | Phytohemagglutinins | 1 | 1998 | 28 | 0.040 |
Why?
| | Interleukin-4 Receptor alpha Subunit | 1 | 2018 | 8 | 0.040 |
Why?
| | Concanavalin A | 1 | 1998 | 75 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2018 | 64 | 0.040 |
Why?
| | Immunocompetence | 1 | 1998 | 43 | 0.040 |
Why?
| | Cells, Cultured | 2 | 2013 | 4106 | 0.040 |
Why?
| | Mitogens | 1 | 1998 | 58 | 0.040 |
Why?
| | Sodium Dodecyl Sulfate | 1 | 1997 | 23 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2010 | 4961 | 0.040 |
Why?
| | Respiratory Function Tests | 2 | 2010 | 598 | 0.040 |
Why?
| | Equipment Design | 2 | 2015 | 526 | 0.040 |
Why?
| | Pollen | 1 | 1997 | 25 | 0.040 |
Why?
| | Cystic Fibrosis | 1 | 2007 | 1065 | 0.040 |
Why?
| | Cladosporium | 1 | 1997 | 1 | 0.040 |
Why?
| | Mitosporic Fungi | 1 | 1997 | 7 | 0.040 |
Why?
| | Organophosphonates | 1 | 1998 | 92 | 0.040 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 1997 | 57 | 0.040 |
Why?
| | Evaluation Studies as Topic | 1 | 1997 | 175 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2018 | 140 | 0.040 |
Why?
| | Cross Reactions | 1 | 1997 | 130 | 0.040 |
Why?
| | Herpes Simplex | 1 | 1998 | 94 | 0.030 |
Why?
| | Colony Count, Microbial | 1 | 1997 | 117 | 0.030 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1997 | 327 | 0.030 |
Why?
| | Immunoblotting | 1 | 1997 | 304 | 0.030 |
Why?
| | Drug Interactions | 1 | 1998 | 370 | 0.030 |
Why?
| | Superantigens | 1 | 1997 | 71 | 0.030 |
Why?
| | Enterotoxins | 1 | 1997 | 89 | 0.030 |
Why?
| | Prognosis | 1 | 2005 | 3830 | 0.030 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1998 | 226 | 0.030 |
Why?
| | Immunization | 1 | 1999 | 416 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2009 | 5400 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 2022 | 771 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2023 | 5083 | 0.030 |
Why?
| | JC Virus | 1 | 2016 | 23 | 0.030 |
Why?
| | Workflow | 1 | 2017 | 150 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2018 | 521 | 0.030 |
Why?
| | Indoles | 1 | 1998 | 379 | 0.030 |
Why?
| | Therapeutic Equivalency | 1 | 2015 | 20 | 0.030 |
Why?
| | Pharmacokinetics | 1 | 2015 | 25 | 0.030 |
Why?
| | IgA Deficiency | 1 | 1994 | 6 | 0.030 |
Why?
| | Biopsy | 2 | 2011 | 1107 | 0.030 |
Why?
| | Gene Expression Regulation | 2 | 2016 | 2549 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 1999 | 1101 | 0.030 |
Why?
| | Pericarditis | 1 | 1994 | 12 | 0.030 |
Why?
| | Seasons | 1 | 1997 | 503 | 0.030 |
Why?
| | Sulfonamides | 1 | 1998 | 502 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2004 | 1712 | 0.030 |
Why?
| | Radionuclide Imaging | 1 | 1994 | 126 | 0.030 |
Why?
| | Internationality | 1 | 2015 | 150 | 0.030 |
Why?
| | Self Report | 1 | 2018 | 802 | 0.030 |
Why?
| | Constriction, Pathologic | 1 | 1994 | 231 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 2016 | 363 | 0.030 |
Why?
| | Risk Factors | 1 | 2008 | 9865 | 0.030 |
Why?
| | Viral Load | 1 | 2016 | 452 | 0.030 |
Why?
| | Receptors, Interleukin-5 | 1 | 2013 | 6 | 0.030 |
Why?
| | Suppressor of Cytokine Signaling Proteins | 1 | 2013 | 21 | 0.030 |
Why?
| | Hypersensitivity, Immediate | 1 | 2013 | 48 | 0.030 |
Why?
| | Arachidonic Acid | 1 | 2013 | 115 | 0.030 |
Why?
| | Flow Cytometry | 1 | 1997 | 1158 | 0.030 |
Why?
| | Disease Management | 1 | 2017 | 597 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 780 | 0.030 |
Why?
| | Staphylococcus aureus | 1 | 1997 | 431 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 1998 | 1210 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 328 | 0.020 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 1994 | 252 | 0.020 |
Why?
| | Histocytochemistry | 1 | 2011 | 81 | 0.020 |
Why?
| | Efficiency | 1 | 2012 | 95 | 0.020 |
Why?
| | Autoimmune Diseases | 1 | 1994 | 426 | 0.020 |
Why?
| | Prospective Studies | 1 | 2023 | 7131 | 0.020 |
Why?
| | Nasal Mucosa | 1 | 2011 | 107 | 0.020 |
Why?
| | Eosinophil Cationic Protein | 1 | 2010 | 10 | 0.020 |
Why?
| | Interleukin-5 Receptor alpha Subunit | 1 | 2010 | 6 | 0.020 |
Why?
| | Lymphopenia | 1 | 2010 | 60 | 0.020 |
Why?
| | Models, Biological | 1 | 1997 | 1716 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2011 | 405 | 0.020 |
Why?
| | Injections, Subcutaneous | 1 | 2009 | 146 | 0.020 |
Why?
| | Cell Count | 1 | 2010 | 320 | 0.020 |
Why?
| | Cats | 1 | 2009 | 211 | 0.020 |
Why?
| | Occupational Health | 1 | 2012 | 195 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2009 | 274 | 0.020 |
Why?
| | Sleep Wake Disorders | 1 | 2012 | 251 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2016 | 3185 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2010 | 396 | 0.020 |
Why?
| | Emotions | 1 | 2012 | 537 | 0.020 |
Why?
| | Up-Regulation | 1 | 2009 | 856 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2009 | 1291 | 0.020 |
Why?
| | Exercise Test | 1 | 2009 | 622 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2010 | 730 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2009 | 1983 | 0.010 |
Why?
| | ROC Curve | 1 | 2005 | 507 | 0.010 |
Why?
| | Brain | 1 | 2016 | 2629 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2013 | 5365 | 0.010 |
Why?
| | Spectrophotometry | 1 | 2001 | 59 | 0.010 |
Why?
| | Apoptosis | 1 | 2010 | 2519 | 0.010 |
Why?
| | Rheology | 1 | 2001 | 91 | 0.010 |
Why?
| | Sodium Chloride | 1 | 2001 | 142 | 0.010 |
Why?
| | Particle Size | 1 | 2001 | 354 | 0.010 |
Why?
| | Cytosine | 1 | 1998 | 46 | 0.010 |
Why?
| | Organophosphorus Compounds | 1 | 1998 | 78 | 0.010 |
Why?
| | Mice | 1 | 2013 | 16832 | 0.010 |
Why?
|
|
Katial's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|